Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 12:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 12,245 matching trials from the live ClinicalTrials.gov search.
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Waterbury, Connecticut • Brooksville, Florida • Immokalee, Florida + 6 more
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
121
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
Conditions
Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
9,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
213
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 24 Months
Enrollment
2,432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Denver, Colorado + 12 more
Conditions
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
Drug
Lead sponsor
VM Oncology, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
12
States / cities
Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 9 more
Completed Not applicable Interventional Results available

Active Bathing to Eliminate Infection (ABATE Infection) Trial

NCT02063867
Conditions
Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms
Interventions
Arm 2: Decolonization
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
52
States / cities
West Hills, California • Thornton, Colorado • Bradenton, Florida + 42 more
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Interventions
Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells, Fludarabine, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alagille Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Colorectal Cancer
Interventions
Futuximab/modotuximab, Trifluridine/Tipiracil
Biological · Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Conditions
Diabetes Mellitus, Type 2
Interventions
MK-1403 + additive coformulation, Placebo + additive coformulation
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 2 more
Enrolling by invitation No phase listed Observational

Persona SoluTion PPS Femur PMCF

NCT07286513
Conditions
Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis), Polyarthritis, Collagen Disorders, Avascular Necrosis of Femoral Condyle, Valgus Deformity, Varus Deformity, Flexion Deformity of Knee
Interventions
Total knee arthroplasty
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
5
States / cities
Denver, Colorado • Louisville, Kentucky • Baltimore, Maryland + 1 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
fenretinide
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
Completed No phase listed Observational

JC-Virus (JCV) Antibody Program

NCT01070823
Conditions
Multiple Sclerosis
Interventions
Tysabri® (natalizumab)
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
1,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Cullman, Georgia + 8 more
Conditions
Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
Interventions
Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Tacrolimus
Drug · Procedure
Lead sponsor
Hannah Choe, MD
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio
Conditions
Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
Interventions
[18F]florbetaben
Drug
Lead sponsor
Lantheus Germany GmbH
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Kansas City, Kansas • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Conditions
Esophagus Cancer, Esophageal Cancer Stage, Esophageal Cancer, Esophageal Neoplasms, Esophagus Adenocarcinoma, Esophagus, Barrett, Barrett Esophagus, Barrett Adenocarcinoma, Barrett Epithelium, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Barretts Esophagus With High Grade Dysplasia, Barretts Esophagus With Low Grade Dysplasia, Barrett Esophagus, Long-Segment, Barrett's Esophagus With Dysplasia, Unspecified, Barrett's Esophagus With Esophagitis, Gastroesophageal Reflux, Reflux Disease, Esophageal Adenocarcinoma, Esophageal Dysplasia, Esophageal Neoplasms Malignant
Interventions
EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
658 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Duarte, California
Conditions
B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions
Samalizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Morristown, New Jersey + 1 more
Conditions
Spinal Cord Injuries
Interventions
Acute Intermitted Hypoxia, Massed Practise, Rapael Glove
Other · Procedure
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • East Hanover, New Jersey
Conditions
Multiple Myeloma Bone Disease
Interventions
BHQ880, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Boston, Massachusetts + 2 more
Conditions
Leukemia
Interventions
allogeneic hematopoietic stem cell transplantation, CliniMACS
Procedure · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Neurodevelopmental Disorders
Interventions
Intensive interdisciplinary therapy
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
7 Years to 17 Years
Enrollment
4 participants
Timeline
2023
U.S. locations
1
States / cities
Columbia, Missouri